Search Results
Mar 19, 2026, 08:10 ET Ractigen Therapeutics Announces China NMPA IND Approval for Phase II Clinical Trial of saRNA Therapy RAG-01 in Non-Muscle Invasive Bladder Cancer
small activating RNA (saRNA) therapeutics, today announced that China's National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) has approved its Investigational New Drug (IND) application to initiate a Phase II clinical trial of RAG-01 for the treatment of Non-Muscle Invasive
More news about: Ractigen Therapeutics
Mar 19, 2026, 07:00 ET Brii Biosciences Provides Corporate Updates and Reports Full Year 2025 Financial Results
ENHANCE studies expected to be announced in 2H 2026.In parallel, the Company has engaged with the Center for Drug Evaluation (CDE) of National Medical Products Administration (NMPA) to discuss potential Phase 3 study designs and primary endpoints. Results from the ongoing ENRICH
More news about: Brii Biosciences Limited
Mar 18, 2026, 10:00 ET High-Margin Mining: How the Smart Money Is Navigating the New Gold Supercycle
this environment, Lake Victoria Gold Ltd. (TSXV: LVG) (OTCQB: LVGLF), Equinox Gold (NYSE-A: EQX) (TSX: EQX), Coeur Mining (NYSE: CDE), New Gold (NYSE-A: NGD) (TSX: NGD), and Aris Mining (NYSE: ARIS) (TSX: ARIS) represent the players (near-producers and producers alike)
More news about: USA News Group
Mar 14, 2026, 00:33 ET Vimgreen's Novel A2AR Antagonist Receives CDE IND Approval for NASH/MASH Therapy
steatohepatitis (NASH), increasingly referred to as metabolic dysfunction‑associated steatohepatitis (MASH), by the China's Center for Drug Evaluation (CDE). This achievement represents the second clinical indication for the company's lead drug candidate, complementing its ongoing development program for
More news about: Vimgreen Pharmaceuticals
Mar 06, 2026, 07:03 ET CARsgen Therapeutics Announces 2025 Annual Results
Claudin18.2. In China, satri-cel was granted Breakthrough Therapy Designation (BTD) in March 2025 and Priority Review in May 2025 by the CDE. In June 2025, the CDE of NMPA of China has accepted the NDA for satri-cel for the treatment of Claudin18.2-positive advanced gastric/gastroesophageal junction
More news about: CARsgen Therapeutics
Mar 05, 2026, 09:00 ET The Numbers Are In: Silver Mining's Best Year Just Set a New Floor
capital toward Americore Resources (TSXV: AMCO) (OTCQB: AMCOF), Pan American Silver (NYSE: PAAS) (TSX: PAAS), Coeur Mining (NYSE: CDE), First Majestic Silver (NYSE: AG) (TSX: AG), and Endeavour Silver (NYSE: EXK) (TSX: EDR).
More news about: USA News Group
Mar 02, 2026, 09:00 ET ReviR Therapeutics Announces First Participant Dosed in Phase 1 Study and Secures CDE Clearance for Two Orphan Indications in China, Supporting Future U.S. Expansion Strategy
(FIH) Phase 1 clinical trial of its lead candidate, RTX-117. This clinical progress follows the recent clearance by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) of Investigational New Drug (IND) applications for two rare neurological indications: Charcot-Marie-Tooth
More news about: ReviR Therapeutics
Feb 24, 2026, 16:05 ET MATSON, INC. ANNOUNCES FOURTH QUARTER AND FULL YEAR 2025 RESULTS; PROVIDES 2026 OUTLOOK
https://register-conf.media-server.com/register/BI2f86b7aed35545c9bacf93a43078cde7Registered participants will receive the conference call dial-in number and a unique PIN code to access
More news about: Matson, Inc.
Feb 09, 2026, 08:59 ET Florida Community Loan Fund to Deploy $260 Million in Financing to Support Low-Income Individuals and Communities across Florida
CDFI and CDE through the U.S. Department of Treasury and as a member of the Federal Home Loan Bank of Atlanta. Learn more at
More news about: Florida Community Loan Fund (FCLF)
Feb 05, 2026, 21:26 ET Akeso Receives Fifth Breakthrough Therapy Designation from NMPA for Ivonescimab in First-Line Treatment of Advanced Biliary Tract Cancer
first-in-class bispecific antibody targeting PD-1 and VEGF, has been granted its fifth Breakthrough Therapy Designation from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). This latest designation applies to ivonescimab in combination with chemotherapy for the first-line
More news about: Akeso, Inc.
Feb 02, 2026, 08:07 ET DXC nomme Rob Le Busque à la tête de la région Asie-Pacifique et Japon
puissante d'expertise régionale, de leadership commercial et d'engagement profond envers les clients », a déclaré T.R. Newcomb, chief revenue officer cde DXC. « Qu'il s'agisse de diriger des marchés vastes et diversifiés ou d'établir des relations de confiance avec certaines des organisations les plus
More news about: DXC Technology Company
Jan 30, 2026, 17:00 ET New Gold Obtains Final Court Approval for Plan of Arrangement with Coeur Mining
arrangement under the Business Corporations Act (British Columbia), whereby a wholly-owned subsidiary of Coeur Mining, Inc. ("Coeur") (NYSE: CDE) will acquire all of the issued and outstanding common shares of New Gold (the "Transaction").The Transaction remains subject to approval under
More news about: New Gold Inc.
Jan 28, 2026, 21:21 ET QureBio Ltd. to Present at ASCO 2026 its Q-1802 Phase II Clinical Results
advanced GC/GEJ, supporting a phase III trial with Q-1802 10 mg/kg as recommended dose.Q-1802 phase III trial has recently been approved by Chinese CDE.About Q-1802 Q-1802, a humanized Claudin18.2/PD-L1 bispecific antibody, kills tumors by both innate immunity such as antibody-dependent
More news about: QureBio Ltd.
Jan 27, 2026, 17:00 ET Shareholders Overwhelmingly Support Plan of Arrangement with Coeur Mining
arrangement under the Business Corporations Act (British Columbia), whereby a wholly-owned subsidiary of Coeur Mining, Inc. ("Coeur") (NYSE: CDE) will acquire all of the issued and outstanding common shares of New Gold (the "Transaction").
More news about: New Gold Inc.
Jan 27, 2026, 03:18 ET Libevitug Approved in China as First-in-Class Treatment for Hepatitis D
addressing a major clinical gap in this field. The drug previously received "Breakthrough Therapy Designation" from both the Center for Drug Evaluation (CDE) of the China NMPA and the U.S. Food and Drug Administration (FDA).
More news about: Huahui Health Ltd.
Jan 21, 2026, 10:30 ET PHFA, CCG announce $65M in New Markets Tax Credits to enhance Pennsylvania communities
Pa., Jan. 21, 2026 /PRNewswire/ -- Commonwealth Cornerstone Group, a nonprofit community development entity (CDE) created by Pennsylvania Housing Finance Agency, has been awarded $65 million in New Markets Tax Credit allocations, the agency announced today. The
More news about: Pennsylvania Housing Finance Agency
Jan 20, 2026, 10:00 ET NEW YORK CITY REGIONAL CENTER-MANAGED COMPANY AWARDED $75 MILLION IN NEW MARKET TAX CREDIT ALLOCATION FROM U.S. TREASURY DEPARTMENT
Since 2016, NYCR-CDE has received eight separate annual tax credit awards totaling $390 million from the Department of Treasury. To receive an award, NYCR-CDE was required to demonstrate a mission and track record of providing investment capital
More news about: New York City Regional Center
Jan 19, 2026, 17:57 ET Glass Lewis Recommends New Gold Shareholders Vote "FOR" the Plan of Arrangement with Coeur Mining
arrangement under the Business Corporations Act (British Columbia), pursuant to which a wholly-owned subsidiary of Coeur Mining, Inc. ("Coeur") (NYSE: CDE) will acquire all of the issued and outstanding common shares of New Gold (the "Transaction"), to be approved at the upcoming Special Meeting of New
More news about: New Gold Inc.
Jan 19, 2026, 06:24 ET Akeso Announces NMPA Acceptance of Second NDA for Gumokimab (IL-17A Inhibitor) in Active Ankylosing Spondylitis
anti-IL-17A monoclonal antibody for the treatment of active ankylosing spondylitis (AS), has been accepted for review by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). There are approximately 4 million AS patients in China, and gumokimab represents a potentially
More news about: Akeso, Inc.
Jan 14, 2026, 22:03 ET MATSON ANNOUNCES PRELIMINARY 4Q25 RESULTS, PROVIDES 2026 OUTLOOK AND ANNOUNCES 4Q25 EARNINGS CALL DATE
https://register-conf.media-server.com/register/BI2f86b7aed35545c9bacf93a43078cde7Registered participants will receive the conference call dial-in number and a unique PIN code to access
More news about: Matson, Inc.
Jan 13, 2026, 17:00 ET ISS Recommends New Gold Shareholders Vote "FOR" the Plan of Arrangement with Coeur Mining
arrangement under the Business Corporations Act (British Columbia), pursuant to which a wholly-owned subsidiary of Coeur Mining, Inc. ("Coeur") (NYSE: CDE) will acquire all of the issued and outstanding common shares of New Gold (the "Transaction"), to be approved at the upcoming special meeting of New
More news about: New Gold Inc.
Jan 13, 2026, 07:30 ET Ractigen Therapeutics Announces First Patient Dosed in Phase II Clinical Trial of RAG-17 for SOD1-ALS
Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) and been selected for the CARE Program of the Center for Drug Evaluation (CDE), National Medical Products Administration (NMPA), which facilitates the accelerated development of rare disease therapies.About ALSAmyotrophic
More news about: Ractigen Therapeutics
Jan 13, 2026, 01:52 ET Halper Sadeh LLC Encourages CTGO, GBIO, CDE Shareholders to Contact the Firm to Discuss Their Rights
multimedia:https://www.prnewswire.com/news-releases/halper-sadeh-llc-encourages-ctgo-gbio-cde-shareholders-to-contact-the-firm-to-discuss-their-rights-302659405.htmlSOURCE
More news about: Halper Sadeh LLP
Jan 05, 2026, 07:00 ET Kelun-Biotech Receives Investigational New Drug Approval for ITGB6-Targeted ADC SKB105 from the NMPA
CR-003), an internally developed integrin beta-6 (ITGB6)-targeted antibody-drug conjugate (ADC), has been approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China for the treatment of advanced solid tumors.
More news about: Kelun-Biotech
Jan 05, 2026, 04:27 ET Kelun-Biotech Announces Breakthrough Therapy Designation Granted in China for Sacituzumab Tirumotecan (sac-TMT) in Combination with Immunotherapy Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC
monoclonal antibody pembrolizumab (KEYTRUDA®[1]) was granted Breakthrough Therapy Designation (BTD) by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China for the first-line treatment of patients with locally advanced or metastatic non-small
More news about: Kelun-Biotech